x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

OncoPharm

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

science

All Episodes

00:20:35

Mosunetuzumab And Same-day Pegfilgrastim w/ ddAC

OncoPharm ·

2023/01/05

New Year - New Drug, mosunetuzumab (a CD3-CD20 T-cell engager) is approved for r/r Follicular Lymphoma. And an intriguing retrospective cohort study found a higher rate of neutropenia with same-day pegfilgrastim in patients receiving dose-dense AC. Link: https://doi.org/10.1177/10781552221148116

en

00:19:43

2022 New Drug Review

OncoPharm ·

2022/12/29

This gift-giving season, we ask whether we want to Keep, Re-gift, or Return new oncology drugs approved this past year.

en

00:17:07

Project Renewal: Capecitabine

OncoPharm ·

2022/12/22

The FDA's pilot program, project renewal, uses capecitabine for its first label makeover. What's new & what are the possible implications of the DPYD warning now in the prescribing information?

en

00:15:17

ASH 2022 Highlights

OncoPharm ·

2022/12/16

Thought on: Double Dauno, but they said it better --> (https://open.spotify.com/episode/0eHEl3bUdZdg3mynUiNMG6?si=88cdab4b882e4667) Blinatumumab FTW The end of "the" neutropenic diet?

en

00:17:52

TILs, Olutasidenib, T-DXd

OncoPharm ·

2022/12/08

Tumor-Infiltrating Lymphocytes (TILs) getting closer to entering practice. Updated survival results published from DESTINY-Breast03 (T-DXd vs. T-DM1). A new IDH1 inhibitor, olutasidenib, is FDA-approved for relapsed or refractory AML.

en

00:13:54

Bad News For Belantamab-Mafodotin And Atezolizumab's...

OncoPharm ·

2022/12/01

Recent voluntary withdrawals from the US market of belantamab-mafodotin and atezolizumab's indication for bladder cancer have us weighing (again) the pros & cons of the accelerated approval program. Also, FDA approves the 1st fecal transplant product.

en

00:19:29

Mirvetuximab Soravtansine

OncoPharm ·

2022/11/17

A new antibody-drug conjugate is approved for ovarian cancer.

en

00:14:05

Metastatic NSCLC Updates: Role of CTLA-4 inhibitors?

OncoPharm ·

2022/11/10

We review the 5-year update of CheckMate 227 and the POSEIDON to generate the hypothesis that CLTA-4 inhibition has a role in PD-L1 negative metastatic NSCLC. CM 227 update: https://pubmed.ncbi.nlm.nih.gov/?term=36223558 POSEIDON: https://pubmed.ncbi.nlm.nih.gov/?term=36327426 Editorial: https://pubmed.ncbi.nlm.nih.gov/?term=36331243

en

00:10:44

No Room for MABs at the INN

OncoPharm ·

2022/11/03

The International Nonproprietary Names (INN) unit from WHO decided to drop the -mab suffix from new drug names. Instead, -tug, -bart, -ment, and -mig will be used. We have some thoughts. INN Report: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122354/#

en

00:23:26

Tremelimumab & Teclistamab

OncoPharm ·

2022/10/27

New Drug Approvals! -Tremelimumab, the 2nd CTLA-4 inhibitor, finally gets approved. -Teclistamab, an excited BCMA-CD3 T-cell engager for multiple myeloma.

en

00:17:48

Pemetrexed Maintenance

OncoPharm ·

2022/10/20

Landmarks of OncoPharm episode on maintenance pemetrexed in NSCLC. Switch maintenance: https://doi.org/10.1016/s0140-6736(09)61497-5 Continuation maintenance (PARAMOUNT): https://doi.org/10.1016/S1470-2045(12)70063-3

en

00:20:04

Allo CAR-T & Aprepitant For EGFR TKI Pruritis

OncoPharm ·

2022/10/13

We discuss a phase I study (CALM) of an allogeneic anti-CD19 CART-T product, using aprepitant (?) for pruritis from EGFR TKIs, and the widely discussed NordICC study on colonoscopy screening. CALM: https://doi.org/10.1016/S2352-3026(22)00245-9 Aprepitant vs. desloratidine: https://doi.org/10.1002/cncr.34474 NordICC: https://www.nejm.org/doi/full/10.1056/NEJMoa2208375 NordICC editorial: https://www.nejm.org/doi/full/10.1056/NEJMe2211595

en

00:16:05

Futibatinib, ESR1, & GPRC5D

OncoPharm ·

2022/10/06

A new FGFR inhibitor, futibatinib, is approved. Is ESR1 mutation monitoring the next thing in HR+ metastatic breast cancer? The PADA-1 trial offers insight. What the heck is GPRC5D (rhymes with CAR-T)? PADA-1: https://doi.org/10.1016/S1470-2045(22)00555-1 GPRC5D CAR-T in Myeloma: https://www.nejm.org/doi/full/10.1056/NEJMoa2209900

en

00:15:56

Thiosulfate And Selpercatinib

OncoPharm ·

2022/09/29

Sodium thiosulfate is now FDA-approved to minimize the risk of ototoxicity in some children receiving cisplatin. Selpercatinib is granted a 'regular' approval for RET-fusion (+) NSCLC and an accelerated approval for other solid tumors.

en

00:10:26

9 22

OncoPharm ·

2022/09/22

Happy 9,22 day!

en

00:11:41

ESMO 2022 - NICHE-2 and Codebreak 200

OncoPharm ·

2022/09/15

ESMO 2022 is wrapped and two studies in particular have caught our eyes: NICHE-2: neoadjuvant Nivo/Ipi in MMR-d colon cancer CODEBREAK: sotorasib vs. docetaxel

en

00:15:56

Biliary Tract Cancer & Pemigatinib (unrelated) Updates

OncoPharm ·

2022/09/09

Updates on billiary track cancer - a role for durvalumab? And pemigatinib - an approval in r/r myeloid/lymphoid neoplasms. Plus, an oral suspension of ibrutinib is approved and more evidence ICI combination should be given early in BRAF-mutated metastatic melanoma (rather than waiting until disease progression on TKIs)

en

00:16:57

Temozolomide + RT For GBM

OncoPharm ·

2022/09/01

The Landmarks of OncoPharm series return to discuss the now standard-of-care temozolomide + RT for glioblastoma multiforme (GBM) Stupp et al: https://www.nejm.org/doi/full/10.1056/NEJMoa043330 Effect of MGMT (the gene, not the band) on temozolomide effect (from the same NEJM issue) referenced, thought not discussed in this episode: https://www.nejm.org/doi/full/10.1056/NEJMoa043331

en

00:39:22

All About Asparaginase

OncoPharm ·

2022/08/25

Dr. Amir Ali joins the Pod to cover the Foundations of OncoPharm on asparaginase products

en

00:14:59

HER2 Mutated NSCLC

OncoPharm ·

2022/08/18

In light of trastuzumab deruxtecan's approval for HER-mutated NSCLC, it's worthwhile to look back at the history of HER-targeted therapy in NSCLC and why/how targeted HER-mutated disease will affect practice.

en

423 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter